ClinicalTrials.gg
CompletedNCT01309828Updated Dec 13, 2013Results posted

Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Hypertension and Kidney Disease

A Phase 3 interventional study of Azilsartan medoxomil and chlorthalidone and Olmesartan medoxomil and hydrochlorothiazide in Safety, sponsored by Takeda. Completed at 55 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-12-13.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
153
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Renal Insufficiency by Takeda — 1 open to participants now, 1 under way, none of them phase 3. Renal Insufficiency · Takeda.

Enrollment
2nd of 11
153 · median 48
Started
2011
the only one that year
Phase 3
2 of 12
none open now
Registered
5th of 12
by date

Among the 12 studies in Renal Insufficiency by Takeda, this one is the 2nd largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2011, is one of 2 in phase 3, and was the 5th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

1 of the 12 studies in Renal Insufficiency by Takeda is open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Renal Insufficiency by Takeda, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate long term safety and tolerability of azilsartan medoxomil and chlorthalidone, once daily (QD), compared with olmesartan medoxomil and hydrochlorothiazide in hypertensive participants with moderate renal impairment.

Read the detailed description

A major component of blood pressure regulation is the renin-angiotensin-aldosterone system (RAAS). Drugs that modulate the RAAS are used commonly worldwide for the treatment of hypertension. TAK-491 (azilsartan medoxomil) is a prodrug of TAK-536 (azilsartan), an angiotensin II receptor blocker (ARB). Azilsartan medoxomil is being evaluated by Takeda to treat participants with essential hypertension.

Chlorthalidone is an orally administered thiazide-like diuretic agent, and long-term outcomes trials show blood pressure reductions associated with chlorthalidone treatment reduce risk of cardiovascular morbidity and mortality.

Hypertensive patients with moderate renal impairment are a relatively more severe and resistant hypertension population, and may benefit from effective fixed-dose combination treatments such as an ARB plus a diuretic for blood pressure control.

Participants will be randomized to receive azilsartan medoxomil and chlorthalidone or olmesartan medoxomil and hydrochlorothiazide for up to 52 weeks to evaluate long term safety of azilsartan medoxomil and chlorthalidone. A titration-to-target blood pressure approach will be used to guide the titration of study medication in this trial.

03

Conditions studied

  • Safety

Keywords

  • Renal Insufficiency
  • Kidney Diseases
  • Hypertension
  • Drug Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is treated with 2 or 3 antihypertensive medications and on stable therapy, defined as ≥6 weeks on medication, and has a mean sitting clinic systolic blood pressure ≥135 and ≤160 mm Hg at the Screening Visit and on Day 1.
  2. Has an estimated (eGFR) in the range of ≥30 to \<60 mL/min/1.73 m\^2 (Stage 3 chronic kidney disease) at the Screening Visit.
  3. Is a man or woman and aged 18 years or older.
  4. A female participant of who is sexually active with a nonsterilized male partner agrees to routinely use adequate from signing of the through 30 days after the last study drug dose.
  5. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
  6. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
  7. Has clinical laboratory test results (clinical chemistry, hematology, and complete urinalysis) that the investigator does not consider to be in this moderate renal impaired population.
  8. Is willing to discontinue the current antihypertensive medications 2 days prior to randomization.

Exclusion criteria

Exclusion Criteria:

  1. Has received any compound within 30 days prior to Screening or is currently participating in another investigational study.
  2. Has been randomized/enrolled in a previous TAK-491 or TAK-491CLD study. NOTE: This criterion does not apply to participants who began participation in another TAK-491 or TAK-491CLD study but were not randomized/enrolled, nor does it apply to participants who participated in observational studies that lacked an intervention or invasive procedure.
  3. Is receiving a combination of olmesartan and hydrochlorothiazide at the Screening Visit.
  4. Is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.
  5. Has a mean clinic diastolic (sitting, trough) >110 mm Hg on Day 1.
  6. Has secondary hypertension of any etiology (eg, renovascular disease, pheochromocytoma, Cushing's syndrome).
  7. Has a recent history (within the last 6 months) of myocardial infarction, heart failure, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebrovascular accident, or .
  8. Has cardiac conduction defects (ie, third-degree atrioventricular block, sick sinus syndrome).
  9. Has hemodynamically significant left ventricular outflow obstruction due to aortic valvular disease.
  10. Has severe renal dysfunction or disease (based on \<30 mL/min/1.73m\^2 at Screening) prior renal transplantation or nephrotic syndrome (defined as a urinary albumin/creatinine ratio >2000 mg/g at Screening).
  11. Has known or suspected unilateral or bilateral renal artery stenosis.
  12. Has a history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug. (This criterion does not apply to those participants with basal cell or stage I squamous cell carcinoma of the skin.)
  13. Has poorly-controlled type 1 or 2 diabetes mellitus (glycosylated A [] >8.5%) at Screening.
  14. Has hypokalemia or hyperkalemia (defined as serum potassium outside of the normal reference range of the central laboratory).
  15. Has an or aspartate aminotransferase level of >2.5 times the , active liver disease, or jaundice.
  16. Has any other known serious disease or condition that would compromise safety, might affect , or make it difficult to successfully manage and follow the participant according to the protocol.
  17. has a history of or allergies to ARBs or thiazide-type diuretics or other sulfonamide-derived compounds.
  18. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within the past 2 years.
  19. Is required to take excluded medications.
  20. If female, is pregnant or lactating or intending to become pregnant before, during, or within 30 days after participating in this study; or intending to donate ova during such time period.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
153 participants (actual)

Study arms

  • Experimental
    Azilsartan Medoxomil + Chlorthalidone

    United States and Europe: Azilsartan medoxomil 20 mg plus chlorthalidone 12.5 mg fixed dose combination tablets, titrated up to azilsartan medoxomil 40 mg plus chlorthalidone 25 mg orally, once daily for up to 52 weeks.

    Drug: Azilsartan medoxomil and chlorthalidone

  • Active comparator
    Olmesartan Medoxomil + Hydrochlorothiazide

    United States: Olmesartan medoxomil 20 mg plus hydrochlorothiazide 12.5 mg fixed dose combination tablets, titrated up to olmesartan medoxomil 40 mg plus hydrochlorothiazide 25 mg orally, once daily for up to 52 weeks. Europe: Olmesartan medoxomil 20 mg plus hydrochlorothiazide 12.5 mg fixed dose combination tablets, titrated up to olmesartan medoxomil 20 mg plus hydrochlorothiazide 25 mg orally, once daily for up to 52 weeks.

    Drug: Olmesartan medoxomil and hydrochlorothiazide

Interventions

  • DrugAzilsartan medoxomil and chlorthalidone

    Drug pages: Azilsartan medoxomil · Chlorthalidone

    Fixed-dose combination tablets.

    Also known as: TAK-491CLD

  • DrugOlmesartan medoxomil and hydrochlorothiazide

    Drug pages: Olmesartan Medoxomil · Hydrochlorothiazide

    Fixed-dose combination tablets.

    Also known as: Olmesartan medoxomil, Hydrochlorothiazide, Benicar hydrochlorothiazide, Olmetec Plus

06

What researchers measure

Primary outcomes

  1. Number of Participants With at Least 1 Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have a causal relationship with this treatment. A serious AE is defined as any untoward medical occurrence that resulted in death, was life threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability or incapacity, led to a congenital anomaly/birth defect or was an important medical event that may have required intervention to prevent any of items above.

    Time frame: From the first dose of open-label study drug until 14 days (or 30 days for a serious adverse event) after the last dose of open- label study drug (up to 56 weeks).

Secondary outcomes

  1. Percentage of Participants at Final Visit Who Achieve Target Systolic Blood Pressure <130 mm Hg

    Systolic blood pressure is the arithmetic mean of the 3 serial sitting systolic blood pressure measurements. Percentage of participants who achieve a sitting clinic systolic blood pressure response defined as less than 130 mm Hg at Week 52.

    Time frame: Week 52

  2. Percentage of Participants at Final Visit Who Achieved Target Diastolic Blood Pressure <80 mm Hg

    Diastolic blood pressure is the arithmetic mean of the 3 serial sitting diastolic blood pressure measurements. Percentage of participants at Week 52 who achieved a sitting clinic diastolic blood pressure response, defined as less than 80 mm Hg.

    Time frame: Week 52

  3. Percentage of Participants at Final Visit Who Achieved Both a Clinic Systolic and Diastolic Blood Pressure Response

    Systolic/diastolic blood pressure is the arithmetic mean of the 3 serial sitting systolic/diastolic blood pressure measurements. Percentage of participants who achieved both a sitting clinic systolic and diastolic blood pressure response, defined as systolic blood pressure less than 130 mm Hg and diastolic blood pressure less than 80 mm Hg at Week 52.

    Time frame: Week 52

07

Results

Posted Dec 13, 2013

Participant flow

Participants took part in the study at 46 investigative sites in the United States, Germany, Latvia, Lithuania, Poland, Slovakia, and the Ukraine from 02 March 2011 to 11 October 2012.

Participant flow — Overall Study
MilestoneAzilsartan Medoxomil + ChlorthalidoneOlmesartan Medoxomil + Hydrochlorothiazide
Started7776
Completed6160
Not completed1616
Withdrew: Adverse event1011
Withdrew: Voluntary withdrawal54
Withdrew: Major protocol deviation01
Withdrew: Other10

Outcome measures

PrimaryNumber of Participants With at Least 1 Adverse Event (AE)

An AE is any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have a causal relationship with this treatment. A serious AE is defined as any untoward medical occurrence that resulted in death, was life threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability or incapacity, led to a congenital anomaly/birth defect or was an important medical event that may have required intervention to prevent any of items above.

Time frame:
From the first dose of open-label study drug until 14 days (or 30 days for a serious adverse event) after the last dose of open- label study drug (up to 56 weeks).
Reported as:
Number · participants
Number of Participants With at Least 1 Adverse Event (AE)
participantsAzilsartan Medoxomil + ChlorthalidoneOlmesartan Medoxomil + Hydrochlorothiazide
Adverse Events6858
Adverse Events Leading to Discontinuation1715
Serious Adverse Events89
Serious Adverse Events Leading to Discontinuation54
Death01
SecondaryPercentage of Participants at Final Visit Who Achieve Target Systolic Blood Pressure <130 mm Hg

Systolic blood pressure is the arithmetic mean of the 3 serial sitting systolic blood pressure measurements. Percentage of participants who achieve a sitting clinic systolic blood pressure response defined as less than 130 mm Hg at Week 52.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants at Final Visit Who Achieve Target Systolic Blood Pressure <130 mm Hg
percentage of participantsAzilsartan Medoxomil + ChlorthalidoneOlmesartan Medoxomil + Hydrochlorothiazide
Percentage of Participants at Final Visit Who Achieve Target Systolic Blood Pressure <130 mm Hg69.3 (57.6 to 79.5)78.4 (67.3 to 87.1)
SecondaryPercentage of Participants at Final Visit Who Achieved Target Diastolic Blood Pressure <80 mm Hg

Diastolic blood pressure is the arithmetic mean of the 3 serial sitting diastolic blood pressure measurements. Percentage of participants at Week 52 who achieved a sitting clinic diastolic blood pressure response, defined as less than 80 mm Hg.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants at Final Visit Who Achieved Target Diastolic Blood Pressure <80 mm Hg
percentage of participantsAzilsartan Medoxomil + ChlorthalidoneOlmesartan Medoxomil + Hydrochlorothiazide
Percentage of Participants at Final Visit Who Achieved Target Diastolic Blood Pressure <80 mm Hg80.0 (69.2 to 88.4)87.8 (78.2 to 94.3)
SecondaryPercentage of Participants at Final Visit Who Achieved Both a Clinic Systolic and Diastolic Blood Pressure Response

Systolic/diastolic blood pressure is the arithmetic mean of the 3 serial sitting systolic/diastolic blood pressure measurements. Percentage of participants who achieved both a sitting clinic systolic and diastolic blood pressure response, defined as systolic blood pressure less than 130 mm Hg and diastolic blood pressure less than 80 mm Hg at Week 52.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants at Final Visit Who Achieved Both a Clinic Systolic and Diastolic Blood Pressure Response
percentage of participantsAzilsartan Medoxomil + ChlorthalidoneOlmesartan Medoxomil + Hydrochlorothiazide
Percentage of Participants at Final Visit Who Achieved Both a Clinic Systolic and Diastolic Blood Pressure Response58.7 (46.7 to 69.9)73.0 (61.4 to 82.6)

Adverse events

Collected over From the first dose of open-label study drug until 14 days (or 30 days for a serious adverse event) after the last dose of open-label study drug (up to 56 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Azilsartan Medoxomil + Chlorthalidone—8/77 (10.4%)52/77 (67.5%)
Olmesartan Medoxomil + Hydrochlorothiazide—9/76 (11.8%)41/76 (53.9%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventAzilsartan Medoxomil + ChlorthalidoneOlmesartan Medoxomil + Hydrochlorothiazide
Angina pectorisCardiac disorders0/772/76
Angina unstableCardiac disorders2/771/76
Coronary artery diseaseCardiac disorders2/771/76
Atrial tachycardiaCardiac disorders0/771/76
BradycardiaCardiac disorders0/771/76
VomitingGastrointestinal disorders0/771/76
ConcussionInjury, poisoning and procedural complications0/771/76
Hip fractureInjury, poisoning and procedural complications0/771/76
Diabetes mellitusMetabolism and nutrition disorders0/771/76
Pituitary tumour recurrentNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/771/76
Most frequent other events
Most frequent other events
EventAzilsartan Medoxomil + ChlorthalidoneOlmesartan Medoxomil + Hydrochlorothiazide
Blood creatinine increasedInvestigations34/7729/76
HeadacheNervous system disorders8/772/76
DizzinessNervous system disorders6/775/76
DiarrhoeaGastrointestinal disorders1/774/76
AstheniaGeneral disorders3/774/76
PharygitisInfections and infestations0/774/76
HyperuricaemiaMetabolism and nutrition disorders3/774/76
BronchitisInfections and infestations4/773/76
HypokalaemiaMetabolism and nutrition disorders4/773/76
HypotensionVascular disorders4/773/76

Baseline characteristics

Age Continuous
Age Continuous(years)Azilsartan Medoxomil + ChlorthalidoneOlmesartan Medoxomil + HydrochlorothiazideTotal
Mean67.9 ± 8.2468.9 ± 9.1068.4 ± 8.66
Age, Customized
Age, Customized(participants)Azilsartan Medoxomil + ChlorthalidoneOlmesartan Medoxomil + HydrochlorothiazideTotal
<45 years011
≥45 to <65 years211839
≥65 to <75 years383977
≥75 years181836
Sex: Female, Male
Sex: Female, Male(Participants)Azilsartan Medoxomil + ChlorthalidoneOlmesartan Medoxomil + HydrochlorothiazideTotal
Female453176
Male324577
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Azilsartan Medoxomil + ChlorthalidoneOlmesartan Medoxomil + HydrochlorothiazideTotal
White5762119
Black or African American181230
Asian224
Region of Enrollment
Region of Enrollment(participants)Azilsartan Medoxomil + ChlorthalidoneOlmesartan Medoxomil + HydrochlorothiazideTotal
Germany10919
Latvia459
Lithuania527
Poland7613
Slovakia6612
Ukraine61117
United States393776
Weight
Weight(kg)Azilsartan Medoxomil + ChlorthalidoneOlmesartan Medoxomil + HydrochlorothiazideTotal
Mean83.54 ± 17.89490.14 ± 21.58786.82 ± 20.025
Height
Height(cm)Azilsartan Medoxomil + ChlorthalidoneOlmesartan Medoxomil + HydrochlorothiazideTotal
Mean165.7 ± 9.65168.7 ± 9.48167.2 ± 9.65
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Azilsartan Medoxomil + ChlorthalidoneOlmesartan Medoxomil + HydrochlorothiazideTotal
Mean30.44 ± 6.22631.57 ± 6.52431.00 ± 6.380

8 further baseline measures are reported on the registry.

08

Study locations

55 sites
  • Kazanlak, Bulgaria
  • Pleven, Bulgaria
  • Sevlievo, Bulgaria
  • Sofia, Bulgaria
  • Varna, Bulgaria
  • Mannheim, Baden Wuerttemberg, Germany
  • Nurnberg, Bayern, Germany
  • Nürnberg, Bayern, Germany
  • Frankfurt, Hessen, Germany
  • Offenbach, Hessen, Germany
  • Rodgau Dudenhofen, Hessen, Germany
  • Essen, Nordrhein Westfalen, Germany
  • Goch, Nordrhein Westfalen, Germany
  • Wuppertal, Nordrhein Westfalen, Germany
  • Berlin, Germany
  • Hamburg, Germany
  • Daugavpils, Latvia
  • Kuldiga, Latvia
  • Limbazi, Latvia
  • Riga, Latvia
  • Tukums, Latvia
  • Ventspils, Latvia
  • Alytus, Lithuania
  • Kaunas, Lithuania
  • Klaipeda, Lithuania
  • Siauliai, Lithuania
  • Vilnius, Lithuania
  • Amsterdam, Netherlands
  • Groningen, Netherlands
  • Maastricht, Netherlands
  • Venlo, Netherlands
  • Grodzisk Mazowiecki, Poland
  • Lodz, Poland
  • Torun, Poland
  • Warszawa, Poland
  • Warszaw, Poland
  • Zgierz, Poland
  • Banska Bystrica, Slovakia
  • Bardejov, Slovakia
  • Bratislava, Slovakia
  • Komarno, Slovakia
  • Kosice, Slovakia
  • Martin, Slovakia
  • Nitra, Slovakia
  • Ruzomberok, Slovakia
  • Svidnik, Slovakia
  • Donetsk, Ukraine
  • Ivano-Frankivsk, Ukraine
  • Kharkiv, Ukraine
  • Kiev, Ukraine
  • Kyiv, Ukraine
  • Lutsk, Ukraine
  • Lviv, Ukraine
  • Vinnitsya, Ukraine
  • Vinnytsya, Ukraine
09

References and documents

Publications

  • Bakris GL, Zhao L, Kupfer S, Juhasz A, Hisada M, Lloyd E, Oparil S. Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease. J Clin Hypertens (Greenwich). 2018 Apr;20(4):694-702. doi: 10.1111/jch.13230. Epub 2018 Mar 4. PubMed 29504252 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2011, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2013, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2011
First posted
Mar 7, 2011
Start
Mar 2011
Primary completionActual
Oct 2012
CompletionActual
Oct 2012
Results first posted
Dec 13, 2013
Last update
Dec 13, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01309828
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Mar 7, 2011
Start date
Mar 2011
Primary completion
Oct 2012
Completion
Oct 2012
Results posted
Dec 13, 2013
Last update
Dec 13, 2013

Study contacts

Medical Director, Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Azilsartan medoxomil · Chlorthalidone

Start the discussion